MedDataX Logo

Comparison of Vascular Remodeling Between Different Antianginal Medication Evaluated by Noninvasive ECG-gated Fundus Photographic Evaluation

NCT ID: NCT01162902

Last Updated: 2013-12-17

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

150 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-09-30

Study Completion Date

2015-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Treatments for stable angina includes drug therapy such as calcium-channel blocker, beta blocker, and ACEI/ARB. To obtain good prognosis in patients with coronary artery disease,preventing or correcting the progression of atherosclerosis and dyslipidemia is more important than relieving angina symptom. Dysfunction of microvessel is one of the most important factor in patients with coronary artery disease. Recently, we developed the new non-invasive method of evaluating the microvessel in fundus. With this methods, we will compare the effect of each drug (beta blocker, CCB, ARB).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Stable Angina

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Diltiazem treated group

Diltiazem 180mg treated group

Group Type EXPERIMENTAL

Diltiazem treated group

Intervention Type DRUG

Diltiazem 180mg for 9 months

Bisoprolol treated group

Bisoprolol 5mg treated group

Group Type ACTIVE_COMPARATOR

Bisoprolol treated group

Intervention Type DRUG

Bisoprolol 5mg for 9 months

Candesartan treated group

Candesartan 32mg treated group

Group Type ACTIVE_COMPARATOR

Candesartan treated group

Intervention Type DRUG

Candesartan 32mg for 9 months

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Diltiazem treated group

Diltiazem 180mg for 9 months

Intervention Type DRUG

Bisoprolol treated group

Bisoprolol 5mg for 9 months

Intervention Type DRUG

Candesartan treated group

Candesartan 32mg for 9 months

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Stable angina patients whose coronary lesions is confirmed by angiography or receives PCI
* Unstable Angina/NSTEMI patients who completed PCI for main lesions
* Either systolic \> 130mmHg or diastolic \> 80mmHg, or patients with anti-hypertensive drugs

Exclusion Criteria

* STEMI patients within one month
* Variant Angina
* Liver function abnormality or renal failure
* History of Hypersensitivity to testing drugs
* Severe heart failure(NYHA class\>3) or uncorrectable hematologic disease
* Woman possible to be pregnant
* Uncontrolled diabetes
* Expected life span \< one year
Minimum Eligible Age

30 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Seoul National University Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Seoul National University Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Seoul National University Hospital

Seoul, , South Korea

Site Status

Countries

Review the countries where the study has at least one active or historical site.

South Korea

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Hae-Young Lee, MD, PhD

Role: CONTACT

Phone: 82-10-4528-6160

Email: [email protected]

Hyo-Soo Kim, MD, PhD

Role: CONTACT

Phone: 82-2-2072-2226

Email: [email protected]

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ABC Trial

Identifier Type: -

Identifier Source: org_study_id